Trial Profile
Controlled, Double-Blind, Randomised, Dose-Ranging Study on the Prevention of VTE (venous thromboembolism) in Patients Undergoing Elective Total Hip Replacement- ODIXa-HIP2 Study BAY 59-7939 [rivaroxaban].
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Enoxaparin sodium
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Therapeutic Use
- Acronyms ODIXa-HIP2 Study
- Sponsors Bayer
- 12 May 2009 Actual initiation date (Jan 2004) added as reported by ClinicalTrials.gov.
- 12 May 2009 Actual end date (Sep 2004) added as reported by ClinicalTrials.gov.
- 27 Nov 2006 New trial record.